Advanced search
1 file | 341.99 KB Add to list

Tumor necrosis factor-alpha augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (DOXIL (R)) correlates with altered DOXIL (R) pharmacokinetics

(2004) INTERNATIONAL JOURNAL OF CANCER. 109(3). p.442-448
Author
Organization

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 341.99 KB

Citation

Please use this url to cite or link to this publication:

MLA
Brouckaert, Peter, et al. “Tumor Necrosis Factor-Alpha Augmented Tumor Response in B16BL6 Melanoma-Bearing Mice Treated with Stealth Liposomal Doxorubicin (DOXIL (R)) Correlates with Altered DOXIL (R) Pharmacokinetics.” INTERNATIONAL JOURNAL OF CANCER, vol. 109, no. 3, 2004, pp. 442–48, doi:10.1002/ijc.11703.
APA
Brouckaert, P., TAKAHASHI, N., VAN TIEL, S., Hostens, J., EGGERMONT, A., SEYNHAEVE, A., … TEN HAGEN, T. (2004). Tumor necrosis factor-alpha augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (DOXIL (R)) correlates with altered DOXIL (R) pharmacokinetics. INTERNATIONAL JOURNAL OF CANCER, 109(3), 442–448. https://doi.org/10.1002/ijc.11703
Chicago author-date
Brouckaert, Peter, N TAKAHASHI, ST VAN TIEL, Jeroen Hostens, AMM EGGERMONT, ALB SEYNHAEVE, Walter Fiers, and TLM TEN HAGEN. 2004. “Tumor Necrosis Factor-Alpha Augmented Tumor Response in B16BL6 Melanoma-Bearing Mice Treated with Stealth Liposomal Doxorubicin (DOXIL (R)) Correlates with Altered DOXIL (R) Pharmacokinetics.” INTERNATIONAL JOURNAL OF CANCER 109 (3): 442–48. https://doi.org/10.1002/ijc.11703.
Chicago author-date (all authors)
Brouckaert, Peter, N TAKAHASHI, ST VAN TIEL, Jeroen Hostens, AMM EGGERMONT, ALB SEYNHAEVE, Walter Fiers, and TLM TEN HAGEN. 2004. “Tumor Necrosis Factor-Alpha Augmented Tumor Response in B16BL6 Melanoma-Bearing Mice Treated with Stealth Liposomal Doxorubicin (DOXIL (R)) Correlates with Altered DOXIL (R) Pharmacokinetics.” INTERNATIONAL JOURNAL OF CANCER 109 (3): 442–448. doi:10.1002/ijc.11703.
Vancouver
1.
Brouckaert P, TAKAHASHI N, VAN TIEL S, Hostens J, EGGERMONT A, SEYNHAEVE A, et al. Tumor necrosis factor-alpha augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (DOXIL (R)) correlates with altered DOXIL (R) pharmacokinetics. INTERNATIONAL JOURNAL OF CANCER. 2004;109(3):442–8.
IEEE
[1]
P. Brouckaert et al., “Tumor necrosis factor-alpha augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (DOXIL (R)) correlates with altered DOXIL (R) pharmacokinetics,” INTERNATIONAL JOURNAL OF CANCER, vol. 109, no. 3, pp. 442–448, 2004.
@article{210480,
  author       = {{Brouckaert, Peter and TAKAHASHI, N and VAN TIEL, ST and Hostens, Jeroen and EGGERMONT, AMM and SEYNHAEVE, ALB and Fiers, Walter and TEN HAGEN, TLM}},
  issn         = {{0020-7136}},
  journal      = {{INTERNATIONAL JOURNAL OF CANCER}},
  language     = {{eng}},
  number       = {{3}},
  pages        = {{442--448}},
  title        = {{Tumor necrosis factor-alpha augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (DOXIL (R)) correlates with altered DOXIL (R) pharmacokinetics}},
  url          = {{http://doi.org/10.1002/ijc.11703}},
  volume       = {{109}},
  year         = {{2004}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: